Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136

Diabetes Care. 2021 Mar;44(3):e61. doi: 10.2337/dci20-0072.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Benzhydryl Compounds
  • Diabetes Mellitus, Type 1* / drug therapy
  • Glucosides
  • Humans
  • Insulin
  • Ketosis*
  • Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

  • Benzhydryl Compounds
  • Glucosides
  • Insulin
  • Sodium-Glucose Transporter 2 Inhibitors
  • dapagliflozin